New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
08:18 EDTROSGRosetta Genomics provides product pipeline update
Rosetta Genomics announces details regarding the company's plans to advance its proprietary microRNA platform technologies in diagnostics and therapeutics. Kenneth A. Berlin, president and CEO of Rosetta Genomics stated, "Rosetta Genomics continues to set the pace in developing and commercializing microRNA-based technologies. We have the most validated microRNA biomarker platform with approximately 50 peer-reviewed publications relating to our platform and have recently rejuvenated our research and development efforts to leverage this leading and versatile platform. We are moving forward on a variety of important projects to provide clinicians with better tools to improve patients' lives in a number of areas of unmet medical need with an aim to commercialize one new assay per year commencing in 2015. Building upon the company's four current commercial diagnostic assays, Rosetta is advancing several new diagnostic assays starting with our lead assay for the differential diagnosis of thyroid neoplasia. In addition, we are evaluating several assays for other cancers as well as assays for non-invasive diagnosis of chronic kidney rejection; the early diagnosis and risk stratification of heart failure patients; and the early diagnosis and differentiation of Alzheimer's disease."
News For ROSG From The Last 14 Days
Check below for free stories on ROSG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
09:31 EDTROSGRosetta Genomics receives final NY approval for its kidney cancer test
Subscribe for More Information
July 10, 2014
09:03 EDTROSGRosetta Genomics receives patent for ovarian cancer treatment
Rosetta Genomics announces receipt of a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application No. 13/977,797, entitled "Compositions and Methods for Treatment of Ovarian Cancer." The patent relates to inhibition of miR-210 for the treatment of ovarian cancer. Treatment for advanced ovarian carcinoma is typically based on the combination of surgery and chemotherapy. The objective of surgical intervention in patients suffering from advanced disease is to perform cyto-reduction to minimal residual disease in the abdominal cavity. Surgery is followed by adjuvant platinum based chemotherapy. Although 80%-90% of patients initially respond to first line treatment, most will either progress during therapy or recur after complete remission. Ovarian cancer causes more deaths than any other gynecologic cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use